MEK inhibitor‐induced paronychia in a paediatric population: A tertiary centre experience-Reference-Cited by-同舟云学术

MEK inhibitor‐induced paronychia in a paediatric population: A tertiary centre experience

Published:2023-05-24 Issue:3 Volume:64 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Palmeiro Ana Gusmão¹^ORCID,Silva Leandro¹^ORCID,Pimentel Bernardo¹,Passos João²³,Moura Cecília⁴,Amaro Cristina¹

Affiliation:

1. Dermatology Department Centro Hospitalar Lisboa Ocidental Lisbon Portugal

2. Neurology Department Instituto Português de Oncologia de Lisboa Francisco Gentil Lisbon Portugal

3. Pediatric Neuro‐Oncology Unit, Pediatrics Department Instituto Português de Oncologia de Lisboa Francisco Gentil Lisbon Portugal

4. Dermatology Department Instituto Português de Oncologia Francisco Gentil Lisbon Portugal

Abstract

AbstractThe cutaneous toxicity of MEK inhibitors may limit treatment adherence. The authors present a retrospective study of 41 paediatric patients with NF‐1 undergoing therapy with selumetinib and propose a treatment algorithm.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14079

Reference23 articles.

1. Selumetinib in Children with Inoperable Plexiform Neurofibromas

2. Treatment of MEK inhibitor‐induced paronychia with doxycycline

3. Adverse cutaneous effects of mitogen‐activated protein kinase inhibitors in children

4. MEK inhibitor-induced chronic paronychia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management;Journal of Clinical Medicine;2024-03-20